Immune cell therapy for patients with COVID-19 related pneumonia using allogenic ex vivo NK cells

Phase 1

• Conditions: SARS-COV-2 related pneumonia.; Coronavirus infection, unspecified; B34.2

• Registration Number: IRCT20200621047859N2
• Lead Sponsor: Motamed Cancer Institute

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 5 January 2021

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

Man or woman, aged 18-70 years
pneumonia that is confirmed by chest imaging (glass turbidity in High-resolution computed tomography[HRCT])
Laboratory confirmation of infection (NCP, Novel Coronavirus Pneumonia) with reverse polymerase chain reaction (RT-PCR) response from any diagnostic sampling source.
Ordinary transthoracic echocardiogram
Adequate kidney function, which is estimated based on glomerular filtration rate (CrCl> 60) ml / min or ml per minute / 1.73 square meters, (CrCl: Creatinine Clearance)

Exclusion Criteria

Pregnancy or lactation
Infection for human immunodeficiency viruses (HIV) , hepatitis B virus (HBV) or hepatitis C virus (HCV)
Patients with other serious systemic diseases or malignancies
Inability to provide informed consent or compliance with test conditions

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Possible hypersensitivity, Allergy symptoms. Timepoint: Daily to release date. Method of measurement: Physical examinations, Vital signs and respiratory symptoms monitoring via ICU equipment's and blood tests.;Improve severe respiratory symptoms. Timepoint: Daily to release date. Method of measurement: Blood oxygen levels, respiration volume, physical examinations.;Anaphylactic shock. Timepoint: Daily to release date. Method of measurement: Physical examinations, Vital signs and respiratory symptoms monitoring via ICU equipment's and blood tests.